ESMO /LinkedIn
May 6, 2025, 06:33
ESMO Deep Dive: Lung Cancer – Advanced Non-small-Cell Lung Cancer 2025
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“In an in-depth exploration of the therapeutic landscape of advanced NSCLC, focusing on critical oncogenes such as EGFR, RAS/RAF, MET, and ERBB2, our expert panel will delve into the molecular mechanisms and clinical implications of these biomarkers, discussing the importance of comprehensive molecular profiling in identifying these mutations.
More posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 15:48
Aug 25, 2025, 15:44
Aug 25, 2025, 15:38
Aug 25, 2025, 15:35
Aug 25, 2025, 15:31
Aug 25, 2025, 15:24
Aug 25, 2025, 15:19
Aug 25, 2025, 15:11
Aug 25, 2025, 15:06